ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Study ID
NCT05787197
Status
Recruiting
Apply to this trial

Conditions

  • Circulating Tumor DNA
  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.

Key Dates

First listed
Mar 28, 2023
Start date
Jan 9, 2024
Status verified
Jul 2025
Primary completion
Sep 25, 2025
Completion
Jun 30, 2027

Study Design

Enrollment
232 participants (estimated)

Primary Outcome Measure

Disease-free survival (DFS) in patients who undergo curative-intent resection of colorectal liver metastasis (CRLM) [ Time Frame: Up to 36 months ]

Central Contacts

Related Studies